Therapeutic options in the treatment of benign prostatic hyperplasia

References

• BerrySJCoffeyDSWalshPCThe development of human benign prostatic hyperplasia with ageJ Urol19841324744796206240
   PubMed Web of Science ®Google Scholar
• RoehrbornCGMcConnellJDEtiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasiaWalshPCRetikABVaughanEDWeinAJCampbell’s UrologyPhiladelphia (PA)Saunders200212971336
   Google Scholar
• McConnellMDBruskewitzRWalshPThe effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasiaN Engl J Med19983385575639475762
   PubMed Web of Science ®Google Scholar
• McConnellJDRoehrbornCGBautistaAMThe long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med200334923852396
   Web of Science ®Google Scholar
• McConnellJDProstatic growth: New insights into hormonal regulationBr J Urol199576Suppl 15107544215
   PubMedGoogle Scholar
• Imperato-McGinleyJGuerreroLGautieerTSteroid 5-alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditismScience1974186121312154432067
   PubMed Web of Science ®Google Scholar
• WalshPCMaddenJDHarrodMJFamilial incomplete male pseudohermaphroditism type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadiasN Engl J Med19742919449494413434
   PubMed Web of Science ®Google Scholar
• ShapiroEHartanoVLeporHQuantifying the smooth muscle content of the prostate using double-immuno-enzymatic staining and color assisted image analysisJ Urol199214711671372663
   PubMed Web of Science ®Google Scholar
• SchwinnDAAndrogen receptors: Unique localization in human tissuesAdv Pharmacol1994313333417532987
   PubMedGoogle Scholar
• LeporHGupDIBaumannMLaboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasiaUrology19983221262462301
   PubMed Web of Science ®Google Scholar
• McConnellJDBarryMJBruskewitzRCBenign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guidelines. No. 8., AHCPR Publication No. 94–0582Rockville, MDAgency for Health Care Policy and ResearchPublic Health Service, US Department of Health and Human Services1994
   Google Scholar
• ChuteCGPanserLAGirmanCJThe prevalence of prostatism: a population-based survey of urinary symptomsJ Urol199315085897685427
   PubMed Web of Science ®Google Scholar
• GirmanCJPanserLAChuteCGNatural history of prostatism: urinary flow rates in a community-based studyJ Urol19931508878927688433
   PubMed Web of Science ®Google Scholar
• BluteMIJacobsenSJKaplanSAEvaluation and management of benign prostatic hyperplasia: proceedings of a thought leader conference held March 31, 2001Urology2001581411750241
   PubMed Web of Science ®Google Scholar
• JacobsenSJJacobsenDJGirmanCJNatural history of prostatism: risk factors for acute urinary retentionJ Urol19971584814879224329
   PubMed Web of Science ®Google Scholar
• RhodesTGirmanCJJacobsenSJLongitudinal prostate growth rates during 5 years in randomly selected men 40–79 years oldJ Urol19991611174117910081864
   PubMed Web of Science ®Google Scholar
• RoehrbornCGBoylePBergnerDSerum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placeboUrology19995466266910510925
   PubMed Web of Science ®Google Scholar
• HoffmanRMMacDonaldRSlatonJWLaser prostatectomy versus transuretheral resection for treating benign prostatic obstruction: a systematic reviewJ Urol200316921021512478138
   PubMed Web of Science ®Google Scholar
• TeAEMalloyTRSteinBSPhotoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trialJ Urol20041721404140815371855
   PubMed Web of Science ®Google Scholar
• ReichOBachmannASiebelsMHigh power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patientsJ Urol200517315816015592063
   PubMed Web of Science ®Google Scholar
• SandhuJSNgCVanderbrinkBAHigh-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostatesUrology2004641155115915596189
   PubMed Web of Science ®Google Scholar
• TunuguntlaHSEvansCPMinimally invasive therapies for benign prostatic hyperplasiaWorld J Urol20022019720612215846
   PubMed Web of Science ®Google Scholar
• GupDIShapiroEBaumanMContractile properties of human prostate adenomas and the development of infravesical obstructionProstate1989151051142477832
   PubMed Web of Science ®Google Scholar
• LeporHAuerbachSPuras-BaezAA randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasiaJ Urol1992148146714741279214
   PubMed Web of Science ®Google Scholar
• FawzyABraunKLewisGPDoxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter studyJ Urol19951541051097539853
   PubMed Web of Science ®Google Scholar
• GillenwaterJYConnRLChrysantSGDoxazosin for the treatment of benign prostatic hyperplasia in patients with mild-to-moderate essential hypertension: a double-blind, placebo controlled, dose-response multicenter studyJ Urol19951541101157539854
   PubMed Web of Science ®Google Scholar
• AUA Practice Guideline CommitteeAUA Guidelines on management of benign prostatic hyperplasia (2003) Chapter 1: Diagnosis and treatment RecommendationsJ Urol200317053054712853821
   PubMed Web of Science ®Google Scholar
• LeporHPhase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator GroupUrology1998518929009609623
   PubMed Web of Science ®Google Scholar
• NarayanPEvansCPMoonTLong-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasiaJ Urol200317049850212853808
   PubMed Web of Science ®Google Scholar
• MartinDJPreclinical pharmacology of a1-adrenoreceptor antagonistsEur Urol199936suppl 1354110393471
   PubMed Web of Science ®Google Scholar
• LukacsBGrangeJCCometDHistory of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 yearsEur Urol20003718319010705197
   PubMed Web of Science ®Google Scholar
• LiXChenCSinghSMThe enzyme and inhibitors of 4-ene-oxosteroid 5 alpha-oxidoreductaseSteroids1995604304417676475
   PubMed Web of Science ®Google Scholar
• RasmussonGHReynoldsGFSteinbergNGAzasteroids: structure-activity relationship for inhibition of 5 alpha-reductase and of androgen receptor bindingJ Med Chem198629229823153783591
   PubMed Web of Science ®Google Scholar
• GromleyGJStonerEBruskewitzRCThe effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study GroupN Engl J Med1992327118511911383816
   PubMed Web of Science ®Google Scholar
• BeislandHOBinkowitzBBrekkanEScandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasiaEur Urol1992222712771283370
   PubMed Web of Science ®Google Scholar
• VaughanDImperato-McginleyJMcConnellJLong-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasiaUrology2002601040104412475666
   PubMed Web of Science ®Google Scholar
• BruskewitzRGirmanCJFowlerJEffect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasiaUrology19995467067810510926
   PubMed Web of Science ®Google Scholar
• KaplanSAHoltgreweHLBruskewitzRComparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasiaUrology2001571073107711377309
   PubMed Web of Science ®Google Scholar
• MatsumotoAMTenoverLMcClungMThe long term effect of specific type II 5-4-year placebo controlled trialJ Urol20021672105210811956450
   PubMed Web of Science ®Google Scholar
• SchaferWTammelaTLJBarrettDMContinued improvement in pressure-flow parameters in men receiving finasteride for 2 yearsUrology19995427828310443725
   PubMed Web of Science ®Google Scholar
• RoehrbornCGBoylePNickelJCEfficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrology20026043444112350480
   PubMed Web of Science ®Google Scholar
• KearneyMCBinghamJBBerglandRClinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasiaJ Urol20021672489249111992064
   PubMed Web of Science ®Google Scholar
• PareekGShevchukMArmenakasNAThe effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patientsJ Urol2003169202312478093
   PubMed Web of Science ®Google Scholar
• HagertyJAGinsbergPCHarmonJDPretreatment with finasteride decreases perioperative bleeding associated with transuretheral resection of the prostateUrology20005568468910792079
   PubMed Web of Science ®Google Scholar
• DonahueJFSharmaHAbrahamRTransuretheral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finaste-ride for decreasing operative blood lossJ Urol20021682024202612394700
   PubMed Web of Science ®Google Scholar
• LeporHWillifordWOBarryMJThe efficacy of terazosin, finasteride, or both in benign prostatic hyperplasiaN Engl J Med19963355335398684407
   PubMed Web of Science ®Google Scholar
• KirbyRSRoehrbornCBoylePEfficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) TrialUrology20036111912612559281
   PubMed Web of Science ®Google Scholar
• BautistaOMKusekJWNybergLMStudy design of the Medical Therapy of Prostate Symptoms (MTOPS) trialControl Clin Trials20032422424312689743
   PubMedGoogle Scholar
• LoweFCMcConnellJDHudsonPBLong-term 6-year experience with finasteride in patients with benign prostatic hyperplasiaUrology20036179179612670567
   PubMed Web of Science ®Google Scholar
• LamJSRomasNALoweFCLong-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-upUrology20036135435812597947
   PubMed Web of Science ®Google Scholar
• WalmsleyKCjertsenCKKaplanSAMedical management of BPH – an updateCampbell’s Urology Updates200422
   Google Scholar
• KaplanSAWalmsleyKTeAeTolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasiaJ Urol20051742273227516280803
   PubMed Web of Science ®Google Scholar
• KaplanSARoehrbornCGRovnerESCarlssonMBavendamTGuanZTolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trialJAMA20062962319232817105794
   PubMed Web of Science ®Google Scholar
• RovnerESKrederKSussmanDOEffect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptomsJ Urol20081801034104118639297
   PubMed Web of Science ®Google Scholar
• RoehrbornCGKaplanSAJonesJSWangJTBavendamTGuanZTolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate SizeEur Urol20095547248118583022
   PubMed Web of Science ®Google Scholar
• KaplanSAGonzalezRRTeAECombination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunctionEur Urol2007511717172317258855
   PubMed Web of Science ®Google Scholar
• StiefCGPorstHNeuserDBenekeMUlbrichEA randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaEur Urol2008531236124418281145
   PubMed Web of Science ®Google Scholar
• McVaryKTRoehrbornCGKaminetskyJCTadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasiaJ Urol20071771401140717382741
   PubMed Web of Science ®Google Scholar
• MariaGBrisindaGCivelloIMBentivoglioARSgangaGAlbaneseARelief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled studyUrology20036225926412893330
   PubMed Web of Science ®Google Scholar
• BrisindaGCadedduFVanellaSMazzeoPMarnigaGMariaGRelief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term resultsUrology200973909418995889
   PubMed Web of Science ®Google Scholar
• LeeRSainiRKaplanSATeAEA Review of Transurethral Microwave ThermotherapyAUA Update Series. Lesson 28, Volume 262007
   Google Scholar
• HoffmanRMMongaMElliotSPMacdonaldRWiltTJMicrowave thermotherapy for benign prostatic hyperplasiaCochrane Database Syst Rev20074CD004135
   Web of Science ®Google Scholar
• BouzaCLópezTMagroANavalpotroLAmateJMSystematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic HyperplasiaBMC Urol200661416790044
   PubMedGoogle Scholar
• MayFHartungRSurgical atlas. Transurethral resection of the prostateBJU Int20069892193416978302
   PubMed Web of Science ®Google Scholar
• ReichOGratzkeCBachmannAUrology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patientsJ Urol200818024624918499179
   PubMed Web of Science ®Google Scholar
• RassweilerJTeberDKuntzRHofmannRComplications of transurethral resection of the prostate (TURP) – incidence, management, and preventionEur Urol20065096997916469429
   PubMed Web of Science ®Google Scholar
• WeiJTCalhounEAJacobsenSJBenign Prostatic HyperplasiaLitwinMSSaigalCSUrologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney DiseasesWashington, DCUS Government Publishing Office2007NIH Publication No. 07–55124370
   Google Scholar
• KaplanSATeAETransurethral electrovaporization of the prostate: a novel method for treating men with benign prostatic hyperplasiaUrology1995455665727536365
   PubMed Web of Science ®Google Scholar
• PoulakisVDahmPWitzschUSuttonAJBechtETransurethral electrovaporization vs transurethral resection for symptomatic prostatic obstruction: a meta-analysisBJU Int200494899515217438
   PubMed Web of Science ®Google Scholar
• BottoHLebretTBarréPOrsoniJLHervéJMLugagnePMElectrovaporization of the prostate with the Gyrus deviceJ Endourol20011531331611339400
   PubMed Web of Science ®Google Scholar
• HoHSYipSKLimKBFookSFooKTChengCWA prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) systemEur Urol20075251752217416453
   PubMed Web of Science ®Google Scholar
• GilleranJPThalyRKChernoffAMRapid communication: bipolar PlasmaKinetic transurethral resection of the prostate: reliable training vehicle for today’s urology residentsJ Endourol20062068368716999627
   PubMed Web of Science ®Google Scholar
• YangQPetersTJDonovanJLWiltTJAbramsPTransurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trialsJ Urol20011651526153211342911
   PubMed Web of Science ®Google Scholar
• CowlesRSKabalinJNChildsSA prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasiaUrology1995461551607542818
   PubMed Web of Science ®Google Scholar
• PypnoWHusiatynskiWTreatment of a benign prostatic hyperplasia by Nd:YAG laser – own experienceEur Urol20003819419810895012
   PubMed Web of Science ®Google Scholar
• GillingPJCassCBCresswellMDMalcolmARFraundorferMRThe use of the holmium laser in the treatment of benign prostatic hyperplasiaJ Endourol1996104594618905494
   PubMed Web of Science ®Google Scholar
• TanAHGillingPJKennettKMFletcherHFraundorferMRLong-term results of high-power holmium laser vaporization (ablation) of the prostateBJU Int20039270770914616451
   PubMed Web of Science ®Google Scholar
• FraundorferMRGillingPJHolmium:YAG laser enucleation of the prostate combined with mechanical morcellation: preliminary resultsEur Urol19983369729471043
   PubMed Web of Science ®Google Scholar
• ElzayatEAElhilaliMMHolmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate, and possible impact of the learning curveEur Urol2007521465147117498867
   PubMed Web of Science ®Google Scholar
• KuntzRMLehrichKAhyaiSAHolmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trialEur Urol20085316016617869409
   PubMed Web of Science ®Google Scholar
• MalekRSBarrettDMKuntzmanRSHigh-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours laterUrology1998512542569495707
   PubMed Web of Science ®Google Scholar
• TeAEMalloyTRSteinBSPhotoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trialJ Urol20041721404140815371855
   PubMed Web of Science ®Google Scholar
• SandhuJSNgCVanderbrinkBAEganCKaplanSATeAEHigh-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostatesUrology2004641155115915596189
   PubMed Web of Science ®Google Scholar
• FuWJHongBFWangXXEvaluation of greenlight photoselective vaporization of the prostate for the treatment of high-risk patients with benign prostatic hyperplasiaAsian J Androl2006836737116625289
   PubMed Web of Science ®Google Scholar
• RuszatRWylerSForsterTSafety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulationEur Urol2007511031103816945475
   PubMed Web of Science ®Google Scholar
• YuXElliottSPWiltTJMcBeanAMPractice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologiesJ Urol200818024124518499180
   PubMed Web of Science ®Google Scholar
• SandhuJSTeAEOpen ProstatectomyAtlas of Urology Clinics2002101725
   Google Scholar